Published in Stat Med on April 11, 2012
Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. Clin Infect Dis (2015) 1.45
Invited Commentary: Every Good Randomization Deserves Observation. Am J Epidemiol (2015) 1.41
Directed Acyclic Graphs for Oral Disease Research. J Dent Res (2016) 1.36
Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches. AIDS (2013) 1.34
The parametric g-formula for time-to-event data: intuition and a worked example. Epidemiology (2014) 1.22
Analysis of occupational asbestos exposure and lung cancer mortality using the g formula. Am J Epidemiol (2013) 1.15
From exposures to population interventions: pregnancy and response to HIV therapy. Am J Epidemiol (2014) 1.13
Changes in fish consumption in midlife and the risk of coronary heart disease in men and women. Am J Epidemiol (2013) 1.08
Invited commentary: Agent-based models for causal inference—reweighting data and theory in epidemiology. Am J Epidemiol (2014) 1.00
What matters most: quantifying an epidemiology of consequence. Ann Epidemiol (2015) 0.93
Growth and Mortality Outcomes for Different Antiretroviral Therapy Initiation Criteria in Children Ages 1-5 Years: A Causal Modeling Analysis. Epidemiology (2016) 0.92
G-computation demonstration in causal mediation analysis. Eur J Epidemiol (2015) 0.91
Risk. Am J Epidemiol (2015) 0.89
Causal mediation analysis with multiple mediators. Biometrics (2014) 0.89
The Impact of Implementation Fidelity on Mortality Under a CD4-Stratified Timing Strategy for Antiretroviral Therapy in Patients With Tuberculosis. Am J Epidemiol (2015) 0.85
The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11. Int J Epidemiol (2016) 0.84
Illustration of a measure to combine viral suppression and viral rebound in studies of HIV therapy. J Acquir Immune Defic Syndr (2015) 0.77
Simulation from a known Cox MSM using standard parametric models for the g-formula. Stat Med (2013) 0.77
An Illustration of Inverse Probability Weighting to Estimate Policy-Relevant Causal Effects. Am J Epidemiol (2016) 0.76
Commentary: The Limits of Risk Factors Revisited: Is It Time for a Causal Architecture Approach? Epidemiology (2017) 0.75
Reduction in diarrhoeal rates through interventions that prevent unnecessary antibiotic exposure early in life in an observational birth cohort. J Epidemiol Community Health (2015) 0.75
Smoking, HIV, and risk of pregnancy loss. AIDS (2016) 0.75
Imputation approaches for potential outcomes in causal inference. Int J Epidemiol (2015) 0.75
Non-operative anti-caries agents and dental caries increment among adults at high caries risk: a retrospective cohort study. BMC Oral Health (2015) 0.75
On the potential of academic epidemiology. Eur J Epidemiol (2017) 0.75
Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep (1992) 22.29
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol (1987) 17.36
A structural approach to selection bias. Epidemiology (2004) 16.44
The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology (1998) 12.32
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet (2005) 6.60
The consistency statement in causal inference: a definition or an assumption? Epidemiology (2009) 6.36
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
Estimating causal effects from epidemiological data. J Epidemiol Community Health (2006) 5.61
Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol (2006) 5.25
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet (1998) 4.54
The control of confounding by intermediate variables. Stat Med (1989) 3.90
A graphical approach to the identification and estimation of causal parameters in mortality studies with sustained exposure periods. J Chronic Dis (1987) 3.63
Illustrating bias due to conditioning on a collider. Int J Epidemiol (2009) 3.54
Implementation of G-computation on a simulated data set: demonstration of a causal inference technique. Am J Epidemiol (2011) 3.29
Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf (2005) 3.05
Toward Causal Inference With Interference. J Am Stat Assoc (2008) 2.85
Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol (2009) 2.48
Invited commentary: positivity in practice. Am J Epidemiol (2010) 2.33
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS (2008) 2.25
Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol (2005) 2.20
Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol (2007) 2.00
Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. Am J Epidemiol (2004) 1.94
Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula. Stat Biosci (2011) 1.73
Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization. Epidemiology (2010) 1.64
Structural nested mean models for assessing time-varying effect moderation. Biometrics (2009) 1.28
Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. AIDS (2008) 1.16
A simple G-computation algorithm to quantify the causal effect of a secondary illness on the progression of a chronic disease. Stat Med (2009) 1.06
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Constructing inverse probability weights for marginal structural models. Am J Epidemiol (2008) 12.39
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet (2002) 9.66
Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology (2009) 9.00
Fallibility in estimating direct effects. Int J Epidemiol (2002) 8.34
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet (2005) 6.60
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med (2005) 6.02
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed (2004) 5.11
Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis (2011) 4.79
Competing risk regression models for epidemiologic data. Am J Epidemiol (2009) 4.75
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA (2007) 4.40
The birth weight "paradox" uncovered? Am J Epidemiol (2006) 4.38
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
Impact of HIV infection and HAART on serum lipids in men. JAMA (2003) 4.01
Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol (2006) 3.84
Use of multiple imputation in the epidemiologic literature. Am J Epidemiol (2008) 3.76
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Epidemiology, data sharing, and the challenge of scientific replication. Epidemiology (2009) 3.49
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med (2014) 3.24
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Gout and risk of Parkinson disease: a prospective study. Neurology (2007) 3.09
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf (2005) 3.05
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 2.90
Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures. Stat Med (2004) 2.87
Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int (2002) 2.83
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr (2007) 2.73
C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med (2006) 2.67
Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis (2007) 2.67
Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis (2004) 2.66
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr (2011) 2.65
Causal directed acyclic graphs and the direction of unmeasured confounding bias. Epidemiology (2008) 2.60
Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS (2003) 2.60
Racial disparities in HIV virologic failure: do missed visits matter? J Acquir Immune Defic Syndr (2009) 2.58
Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis (2007) 2.55
Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology (2008) 2.51
When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat (2010) 2.50
Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol (2009) 2.48
Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer (2006) 2.47
Development of a quality-of-life questionnaire for adults with strabismus. Ophthalmology (2008) 2.46
Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev (2005) 2.45
Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol (2006) 2.45
Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS (2005) 2.42
High incidence and prevalence of HIV-1 infection in high risk population in Calcutta, India. Int J STD AIDS (2003) 2.41
Invited commentary: positivity in practice. Am J Epidemiol (2010) 2.33
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32
Driving status and risk of entry into long-term care in older adults. Am J Public Health (2006) 2.32
Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr (2011) 2.32
Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. J Infect Dis (2009) 2.26
Commentary: A structural approach to Berkson's fallacy and a guide to a history of opinions about it. Int J Epidemiol (2014) 2.23
Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst (2004) 2.23
Commentary: how to report instrumental variable analyses (suggestions welcome). Epidemiology (2013) 2.22
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol (2011) 2.20
Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol (2005) 2.20
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis (2012) 2.16
Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS (2007) 2.10
Missing doses in the life span study of Japanese atomic bomb survivors. Am J Epidemiol (2013) 2.08
Neighborhood poverty and injection cessation in a sample of injection drug users. Am J Epidemiol (2010) 2.07
The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. PLoS Med (2011) 2.06
Invited Commentary: Causal diagrams and measurement bias. Am J Epidemiol (2009) 2.06
Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis (2008) 2.06
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
A Comparison of Agent-Based Models and the Parametric G-Formula for Causal Inference. Am J Epidemiol (2017) 2.05
Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr (2012) 2.03
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One (2013) 2.03
Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol (2002) 2.02
Coronary aging in HIV-infected patients. Clin Infect Dis (2009) 2.02
Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol (2007) 2.00
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS (2010) 1.99
Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol (2009) 1.98
We are number one but nobody cares-that's good. Epidemiology (2012) 1.97
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr (2005) 1.96
Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr (2003) 1.95
Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis (2004) 1.94
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94